Free toolNo sign-up

CDMO FDA inspection lookup

Type a contract manufacturer, a site or an FEI number. See every FDA inspection outcome, warning letter and recall on file for it, by site, in seconds, with the industry's NAI, VAI and OAI split to compare against.

Try: , , ,

Baxter Healthcare Corporation

Deerfield, IL · Devices · Drugs

FDA has published 2 inspections and 26 recalls naming Baxter Healthcare Corporation.

2InspectionsLatest 2026-09-23: Voluntary action indicated · 0% NAI, 50% VAI, 50% OAI
0Warning lettersNone on file
26RecallsLatest 2026-10-21: Class II

Sites: Aibonito, PR (1, latest VAI) · Round Lake, IL (1, latest OAI)

0% of Baxter Healthcare Corporation's inspections closed with no action (NAI), against 44% of the 572 drug inspections FDA has posted with end dates since March 30, 2026 (44% NAI, 47% VAI, 9% OAI).

  • 2026-10-21Class II recallLikorall Overhead Lifts Product Code: 3121001 Product Description: LIKORALL 200 Product Code: 3122005 Product Description: LIKORALL 242 ES, … · DevicesClass IIRecall
  • 2026-09-30Class II recallPRO+ 40" MRS SURFACE, mattress with Advanced Microclimate Technology (AMT) uses a non-powered system of intake and output valves to provide … · DevicesClass IIRecall
  • 2026-09-30Class II recallPRO+ MRS SURFACE FOR VERSACARE, mattress with Advanced Microclimate Technology (AMT) uses a non-powered system of intake and output valves t… · DevicesClass IIRecall
  • 2026-09-30Class II recallBrand Name: VOLARA System Product Name: VOLARA, HC, NA A Model/Catalog Number: M08594A Software Version: N/A Product Description: VOLARA, HO… · DevicesClass IIRecall
  • 2026-09-30Class II recallPRO+ 36" MRS SURFACE, mattress with Advanced Microclimate Technology (AMT) uses a non-powered system of intake and output valves to provide … · DevicesClass IIRecall
  • 2026-09-23FDA inspection: VAIVoluntary action indicated · Drugs · Aibonito, PRVAIInspection
  • 2026-09-16Class I recallDextrose Injection, USP, 70 %, 2000 mL bags, Rx Only, Baxter Healthcare Corporation Deerfield, IL, 60016, Made in USA, NDC 00338-0719-06 · DrugsClass IRecall
  • 2026-09-09Class II recallFamotidine Injection in Sodium Chloride Injection, 20 mg, 50 mL in GALAXY Single Dose Container, Rx Only, Sterile Nonpyrogenic, Baxter Inter… · DrugsClass IIRecall

20 more records: see the company page.

Know the day FDA posts the next one on Baxter Healthcare Corporation

Name the CDMOs you compete with, the sites you run and the biotechs you sell to. One email when FDA inspects, writes to or recalls from any of them, with the record linked. A free account shows every source for the last 7 days. No card.

Start free

What you get

  • Every inspection outcome, by site. NAI, VAI or OAI, the product type and the site, from FDA's Data Dashboard, for 1,782 inspection outcomes with end dates from March 30, 2026 to October 29, 2026. A name finds every site FDA lists under it; an FEI number finds one site and the company behind it.
  • Warning letters and recalls. Each letter with its subject and issuing office; each recall with its class and product, from FDA's own listings, posted since May 20, 2025.
  • The benchmark. The company's share of no-action inspections against the share across all 1,782 inspections held (63% NAI, 34% VAI, 3% OAI), or against the inspections under the same product type when the company has one.
  • The record itself. Every row links to a page that states what FDA published and links to the agency's record.

Why CDMOs check this

Sponsors are checking you. A biotech's quality team looks up a manufacturer's FDA record before an audit, a quote and a tech transfer. This is the page they see, in the words FDA used.

Competitors change on inspection day. An OAI or a warning letter at another site is the week a sponsor starts looking for a second source. The record is public the day FDA posts it.

Your own sites, in one place. One name finds every site FDA lists under it, with the outcome of each visit, instead of one dashboard query per FEI.

What the outcomes mean

NAI
No action indicated. No objectionable conditions were found, or none that justify further action.
VAI
Voluntary action indicated. Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
OAI
Official action indicated. Regulatory or administrative action is recommended. A warning letter, an import alert or a consent decree can follow.

FDA posts a classification after its review of the inspection is complete, often months after the inspection ended. Browse all inspection classifications, warning letters and recalls held, or look a company up in the company directory.

Questions

Inspection classifications are from the FDA Data Dashboard; warning letters from FDA's listing; recalls from FDA's enforcement reports through openFDA. A record may have changed since it was read. The benchmark is a count of the records held, not a rating.

Approve Suite is not affiliated with FDA or with any company shown. See pricing and the FAQ for what the full product does.